Immunology
Trio become latest Symbiosis commercial additions
October 12, 2026CDMO, Devices, Diagnostics, Immunology, clinical trials, pharmaceutical markets
Symbiosis Pharmaceutical Services has further strengthened its commercial team with three new appointments. Payal Roychoudhury and Joaquín Pérez Fornieles join …
UK immunoglobulin supply faces growing pressure, report warns
October 12, 2026Manufacturing and Production Critical supplies, Immunology, NHS Blood and Transplant, Neurology, procurement
The UK may face increasing pressure to secure long-term supplies of immunoglobulin (Ig), with rising demand and heavy reliance on …
Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem.
September 5, 2026Clinical & Scientific, Clinical Research, Clinical Trial Services, Clinical research Training, Clinical trial specialist packaging, Data Capture Asthma & COPD, Chronic Diseases, Immunology, Rare Diseases, Sample integrity, clinical trials, enrolment
By Dr. Richard Graham Industry conversations about clinical trial participation tend to focus on awareness, access, and willingness to enrol. …
AI in pharma: From lab development to patient impact
September 5, 2026AI, Cancer, Immunology, Merck, Vaccine, Virology, personalised medicine, pharma
In the decade to 2025, AI use in vaccine development has increased markedly but is the boom in research translating …
Mavatar announces research collaboration with Sobi
January 6, 2026Research and Development Immunology, Mavatar, Rare Diseases, sobi
Mavatar has announced the initiation of a non-clinical research collaboration with Sobi, using Mavatar’s technology to generate data insights into …
STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases
December 18, 2025Research and Development Bio-Thera, Immunology, Stada
STADA and Bio-Thera’s Gotenfia (golimumab), a biosimilar of Janssen’s Simponi, has received a positive opinion from the European Medicines Agency …
Celltrion’s Remsima IV approved by EC in liquid form
November 27, 2025Research and Development Celltrion Inc, Immunology
Celltrion’s Remsima IV, the first-ever liquid formulation of infliximab for autoimmune diseases, has been approved by the European Commission (EC). …
Alvotech biosimilar receives EC marketing approval
November 26, 2025Research and Development Alvotech, Immunology, Inflammatory disease, Rheumatology
The European Commission (EC) has granted marketing authorisation for Gobivaz, Alvotech’s first-in-market biosimilar of Simponi (golimumab), which is used for …
Chronic spontaneous urticaria – the impact on patient quality of life, ongoing developments in treatments and the importance of greater awareness
October 3, 2025Medical Communications, Research and Development Dermatology, Immunology, acute urticaria, chronic spontaneous urticaria, dermatology, immunology
The current forms of immunotherapy, how T cell therapy works and what the future holds
Neogap Therapeutics appoints Jonas Mattson to its board of directors
August 26, 2025Research and Development Corporate, Immunology, Neogap Therapeutics, Oncology, board of directors
Swedish biotech, Neogap Therapeutics, has appointed Jonas Mattson, an authority in cell therapy, to its board of directors. His appointment …
NICE recommends Benralizumab for Rare Form of Vasculitis
August 15, 2025Medical Communications, Research and Development AstraZeneca, Immunology, National Institute for Health and Care Excellence, vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as an add-on treatment for adult …
Novartis candidate for Sjögren’s disease presents positive results
August 15, 2025Research and Development Immunology, Novartis, Sjögren’s disease, US Food and Drug Administration, clinical trial
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 – evaluating ianalumab in adults …
CuraCell granted approval for trial of new therapy for metastatic cancers
August 13, 2025Research and Development CuraCell, Immunology, clinical trial, immunotherapy, metastic cancer
Swedish immunotherapy company, CuraCell, has received approval from the Paul-Ehrlich-Institut in Germany to begin a phase 1/2a clinical trial of …
A challenge we can no longer ignore: meeting the needs of people with Crohn’s Disease in the UK
August 3, 2025Research and Development Crohn’s disease, Immunology, Lilly UK, autoimmune disease, immunology
By Holly Thomas, Associate Vice-President Specialty Care at Lilly UK and Ireland Immunology care in the UK is at a …
ViroCell Biologics and AvenCell Therapeutics partner to accelerate allogeneic CAR-T therapy development
July 29, 2025Contract Manufacturing, Manufacturing Services, Mergers and Acquisitions, Research and Development AvenCell Therapeutics, CAR-T therapy, Contract Development Manufacturing Organisation, Good Manufacturing Practice, Immunology, Oncology, ViroCell Biologics, autoimmune diseases, blood cancer
ViroCell Biologics has announced a new manufacturing collaboration with AvenCell Therapeutics to produce a high-yield retroviral vector supporting the clinical …
Latest content
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEO
Tridem begins phase Ib trial of Parkinson’s disease vaccine
